Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MiMedx Group, a leader in advanced wound care, announced its virtual 2020 Annual Meeting of Shareholders to be held on November 20, 2020, at 10:00 a.m. Eastern Time. CEO Timothy R. Wright, alongside other senior executives, will present company updates, including commercial and R&D initiatives. Shareholders must log in 15 minutes early to participate via the virtual platform. The definitive proxy statement has been filed with the SEC, and shareholders can access it through the SEC’s website or MiMedx's website.
MiMedx Group, a leader in advanced wound care, announced its upcoming presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 9:30 AM ET. CEO Timothy R. Wright and CFO Peter M. Carlson will represent the company. A live webcast will be available on the company’s website. This forum highlights MiMedx's commitment to innovation in therapeutic biologics, specifically in human placental tissue allografts, which have exceeded two million shipments to date.
MiMedx Group reported third quarter 2020 net sales of $64.3 million, a 28% decrease from $88.9 million in Q3 2019. Adjusted EBITDA reached $6.9 million, or 10.8% of net sales. The company incurred a net loss of $19.4 million, largely attributed to $12.0 million in investigation-related expenses. On a positive note, MiMedx announced its shares were relisted on Nasdaq under ticker MDXG and secured coverage for EpiFix® from the largest U.S. commercial payor, contributing to a planned salesforce expansion.
MiMedx Group, Inc. (NASDAQ: MDXG) announced its participation in the Symposium on Advanced Wound Care Fall, taking place from November 4-6. The company will showcase its new EpiCord Expandable allograft, which can expand to twice its size, enhancing treatment for chronic wounds. Experts will discuss the quality of clinical trials in wound care, emphasizing bias in study designs. MiMedx has processed over two million allografts and aims to improve patient outcomes through innovative products and scientific research.
MiMedx Group, Inc. (OTC PINK: MDXG) announced that its common stock will begin trading on The Nasdaq Stock Market from November 4, 2020. This move marks a significant milestone for the company, which specializes in advanced wound care and therapeutic biologics. MiMedx is recognized for its development and distribution of human placental tissue allografts using its proprietary PURION® process. The company has successfully supplied over two million allografts to the healthcare sector.
MiMedx Group (OTC PINK: MDXG) filed a definitive proxy statement with the SEC for its 2020 Annual Meeting of Shareholders, set for November 20, 2020, at 10:00 a.m. ET. Due to COVID-19 concerns, the meeting will be virtual. Shareholders as of October 7, 2020, can participate and vote. The proxy statement and voting information are being mailed out, with accessible copies on the SEC and MiMedx websites. MiMedx specializes in advanced wound care through human placental tissue allografts, having supplied over 1.9 million allografts to date.